The Zheshang Securities Research Report pointed out that Yuyue Medical's overseas business has performed well, and a rebound in domestic business can be expected. 1H26 achieved net profit of 843 million yuan, yoy -29.92%, and 2Q26 achieved net profit of 414 million yuan, yoy -28.28%. Domestic blood sugar management has performed well, and the export business is growing strongly. From a regional perspective, domestic sales reached 3,726 billion yuan, yoy -7.44%, and export sales reached 824 million yuan, yoy +35.76%. The European and American markets continued to break through. As more product registrations were launched, sales categories gradually became rich, and overseas became an important growth pole driving the company's growth. The company is still a leading company in the industry. New products continue to be launched, market share continues to increase, overseas layout continues to be implemented, and growth has been steady for a long time. As a result, the company's “gain” rating was maintained.

The Zheshang Securities Research Report pointed out that Yuyue Medical's overseas business has performed well, and a rebound in domestic business can be expected. 1H26 achieved net profit of 843 million yuan, yoy -29.92%, and 2Q26 achieved net profit of 414 million yuan, yoy -28.28%. Domestic blood sugar management has performed well, and the export business is growing strongly. From a regional perspective, domestic sales reached 3,726 billion yuan, yoy -7.44%, and export sales reached 824 million yuan, yoy +35.76%. The European and American markets continued to break through. As more product registrations were launched, sales categories gradually became rich, and overseas became an important growth pole driving the company's growth. The company is still a leading company in the industry. New products continue to be launched, market share continues to increase, overseas layout continues to be implemented, and growth has been steady for a long time. As a result, the company's “gain” rating was maintained.